Pharma BD Deal Intelligence

Lonza Group AG / Merck KGaA

2026 · Asset Purchase · Pending

Lonza Group AG signed a definitive agreement on 3 November 2026 to acquire the US contract development and manufacturing (CDMO) network of Merck KGaA, Darmstadt, Germany. The transaction transfers five US manufacturing sites and approximately 1,100 employees, more than doubling Lonza's US CDMO footprint from four to nine sites and taking its US workforce above 6,000. The acquired capabilities span cell and gene therapy, bioconjugates, viral vectors and advanced drug-delivery technologies. VALUE NOT INGESTED: the Lonza media release describes a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs, while trade press (FiercePharma) reported a mid-triple-digit million euro figure; the two are not reconcilable from public disclosure, so deal_value_usd_mm is left NULL rather than estimated. NOTE: ingested at pending_review by bd-enrichment-2026-11-04.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Lonza Group AG deals